Fig. 3.

Model performance verification using clinical studies in older subjects. Concentration–time profiles in the older population. a Simulated (mean—black line) and observed (data points [23]) plasma concentration–time profile after multiple administrations of TDF 300 mg (10 trials × 12 Caucasian subjects, aged 53–66 years). b Simulated (mean—black line) and observed (data points [23]) plasma concentration–time profile after a single administration of 3TC 200 mg (10 trials × 6 Japanese subjects, aged 65–70 years). c Simulated (mean—black line) and observed (data points [23]) plasma concentration–time profile after multiple administrations of FTC 200 mg (10 trials × 12 Caucasian subjects, aged 53–66 years). In all the figures, the grey lines represent mean predictions from individual trials and the dotted lines represent the 5th and 95th percentiles for the predicted data. 3TC lamivudine, FTC emtricitabine, TDF tenofovir